Real-World Data on the Risk of Ventricular Arrhythmias with Sulfonamides

Clin Pharmacol Ther. 2022 Aug;112(2):201-202. doi: 10.1002/cpt.2617. Epub 2022 May 2.

Authors

Alexandre O Gérard^{1

2

3}, Diane Merino¹, Milou-Daniel Drici¹

Affiliations

¹ Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital Center of Nice, Nice, France.
² Department of Nephrology-Dialysis-Transplantation, University Hospital Center of Nice, Nice, France.
³ Laboratory of Molecular Physio Medicine (LP2M), UMR 7370, CNRS, University Côte d'Azur, Nice, France.

PMID: 35500064
DOI: 10.1002/cpt.2617

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Arrhythmia Agents / therapeutic use
Arrhythmias, Cardiac* / chemically induced
Arrhythmias, Cardiac* / epidemiology
Electrocardiography
Humans
Sulfonamides* / adverse effects

Substances

Anti-Arrhythmia Agents
Sulfonamides